COPENHAGEN (Reuters) -Weight-loss and diabetes drugmaker Novo Nordisk (NYSE:) on Wednesday posted third-quarter working revenue in keeping with expectations and narrowed its full-year gross sales and revenue steerage vary.
The maker of well-liked weight-loss drug Wegovy mentioned it now expects gross sales development this yr of between 23% and 27% in native currencies, in comparison with the beforehand guided vary for 22% to twenty-eight% development.
Working revenue development this yr is now seen at between 21% and 27% in native currencies, in comparison with its earlier forecast of 20% to twenty-eight%.
Novo Nordisk has raised its 2024 gross sales development outlook twice for the reason that starting of the yr. In August, nonetheless, the corporate lower its expectations for working revenue development.
“The sales growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, and we are serving more patients than ever before,” CEO Lars Fruergaard Jorgensen mentioned in an announcement.
Novo mentioned working revenue between July and September rose 26% to 33.8 billion Danish crowns ($4.86 billion) in contrast with 33.6 billion forecast by analysts in a ballot gathered by the corporate.
